Analysts’ Top Healthcare Picks: BMRN, GKOS

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BioMarin (NASDAQ: BMRN) and Glaukos (NYSE: GKOS) with bullish sentiments.

BioMarin (NASDAQ: BMRN)

In a report issued on September 13, Ian Somaiya from BMO Capital reiterated a Buy rating on BioMarin (NASDAQ: BMRN), with a price target of $117. The company’s shares opened today at $91.26.

According to TipRanks.com, Somaiya is a 5-star analyst with an average return of 20.0% and a 62.9% success rate. Somaiya covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Aeglea Biotherapeutics Inc, and Corcept Therapeutics Inc.

Currently, the analyst consensus on BioMarin is Strong Buy and the average price target is $111.08, representing a 21.7% upside.

In a report issued on August 30, Citigroup also initiated coverage with a Buy rating on the stock with a $98 price target.
Glaukos (NYSE: GKOS)

BMO Capital analyst Joanne Wuensch reiterated a Buy rating on Glaukos (NYSE: GKOS) yesterday and set a price target of $45. The company’s shares opened today at $33.69.

According to TipRanks.com, Wuensch is a 5-star analyst with an average return of 10.4% and a 72.9% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.

Currently, the analyst consensus on Glaukos is Strong Buy and the average price target is $48.71, representing a 44.6% upside.

In a report released yesterday, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $60 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.